Amgen Inc (AMGN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.92 (+0.33%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Amgen Inc (AMGN)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Key Insights

Critical company metrics and information

  • Share Price

    $278.90

  • Market Cap

    $149.92 Billion

  • Total Outstanding Shares

    537.53 Million Shares

  • Total Employees

    26,700

  • Dividend

    $2.25 Per Share Quarterly

  • IPO Date

    June 17, 1983

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.amgen.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-27.73 Billion
Net Cash Flow From Financing Activities, Continuing$-5.25 Billion
Net Cash Flow From Operating Activities, Continuing$7.26 Billion
Net Cash Flow From Operating Activities$7.26 Billion
Net Cash Flow From Investing Activities$-27.73 Billion
Net Cash Flow$-25.73 Billion
Net Cash Flow, Continuing$-25.73 Billion
Net Cash Flow From Financing Activities$-5.25 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$4.23 Billion
Selling, General, and Administrative Expenses$7.49 Billion
Cost Of Revenue$12.86 Billion
Operating Expenses$13.46 Billion
Income/Loss From Continuing Operations Before Tax$4.68 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Equity Method Investments$-17.00 Million
Operating Income/Loss$6.22 Billion
Income Tax Expense/Benefit$449.00 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Benefits Costs and Expenses$27.86 Billion
Basic Earnings Per Share$7.89
Diluted Average Shares$1.08 Billion
Net Income/Loss Available To Common Stockholders, Basic$4.23 Billion
Costs And Expenses$26.32 Billion
Revenues$32.53 Billion
Gross Profit$19.68 Billion
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss Before Equity Method Investments$4.68 Billion
Diluted Earnings Per Share$7.82
Other Operating Expenses$5.97 Billion
Nonoperating Income/Loss$1.69 Billion
Basic Average Shares$1.07 Billion
Net Income/Loss$4.23 Billion
Income/Loss From Continuing Operations After Tax$4.23 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Current Assets$19.40 Billion
Equity$7.53 Billion
Intangible Assets$28.92 Billion
Liabilities$83.36 Billion
Liabilities And Equity$90.88 Billion
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$2.15 Billion
Other Non-current Liabilities$2.65 Billion
Equity Attributable To Parent$7.53 Billion
Other Non-current Assets$29.04 Billion
Assets$90.88 Billion
Long-term Debt$60.40 Billion
Current Assets$26.77 Billion
Fixed Assets$6.16 Billion
Noncurrent Liabilities$63.04 Billion
Current Liabilities$20.31 Billion
Noncurrent Assets$64.12 Billion
Inventory$7.36 Billion
Other Current Liabilities$18.16 Billion

Historical Dividends

Current dividend: $2.25 Per Share Quarterly
Announcement DatePayment DateRecord DateAmountFrequency
Oct 25, 2024Dec 9, 2024Nov 18, 2024$2.25Quarterly
Aug 2, 2024Sep 6, 2024Aug 16, 2024$2.25Quarterly
Mar 6, 2024Jun 7, 2024May 17, 2024$2.25Quarterly
Dec 12, 2023Mar 7, 2024Feb 16, 2024$2.25Quarterly
Oct 24, 2023Dec 8, 2023Nov 17, 2023$2.13Quarterly
Aug 1, 2023Sep 8, 2023Aug 18, 2023$2.13Quarterly
Mar 7, 2023Jun 8, 2023May 18, 2023$2.13Quarterly
Dec 12, 2022Mar 8, 2023Feb 15, 2023$2.13Quarterly
Oct 28, 2022Dec 8, 2022Nov 17, 2022$1.94Quarterly
Aug 3, 2022Sep 8, 2022Aug 18, 2022$1.94Quarterly
Mar 2, 2022Jun 8, 2022May 17, 2022$1.94Quarterly
Dec 3, 2021Mar 8, 2022Feb 15, 2022$1.94Quarterly
Oct 21, 2021Dec 8, 2021Nov 16, 2021$1.76Quarterly
Jul 30, 2021Sep 8, 2021Aug 17, 2021$1.76Quarterly
Mar 3, 2021Jun 8, 2021May 17, 2021$1.76Quarterly
Dec 16, 2020Mar 8, 2021Feb 15, 2021$1.76Quarterly
Oct 21, 2020Dec 8, 2020Nov 16, 2020$1.6Quarterly
Jul 23, 2020Sep 8, 2020Aug 17, 2020$1.6Quarterly
Mar 4, 2020Jun 8, 2020May 18, 2020$1.6Quarterly
Dec 11, 2019Mar 6, 2020Feb 14, 2020$1.6Quarterly
Oct 22, 2019Dec 6, 2019Nov 15, 2019$1.45Quarterly
Aug 2, 2019Sep 6, 2019Aug 15, 2019$1.45Quarterly
Mar 7, 2019Jun 7, 2019May 17, 2019$1.45Quarterly
Dec 7, 2018Mar 8, 2019Feb 15, 2019$1.45Quarterly
Oct 23, 2018Dec 7, 2018Nov 16, 2018$1.32Quarterly
Jul 31, 2018Sep 7, 2018Aug 17, 2018$1.32Quarterly
Mar 7, 2018Jun 8, 2018May 17, 2018$1.32Quarterly
Dec 12, 2017Mar 8, 2018Feb 15, 2018$1.32Quarterly
Oct 24, 2017Dec 8, 2017Nov 17, 2017$1.15Quarterly
Jul 28, 2017Sep 8, 2017Aug 17, 2017$1.15Quarterly
Mar 7, 2017Jun 8, 2017May 17, 2017$1.15Quarterly
Dec 20, 2016Mar 8, 2017Feb 15, 2017$1.15Quarterly
Oct 14, 2016Dec 8, 2016Nov 16, 2016$1Quarterly
Jul 22, 2016Sep 8, 2016Aug 17, 2016$1Quarterly
Mar 2, 2016Jun 8, 2016May 17, 2016$1Quarterly
Dec 15, 2015Mar 8, 2016Feb 16, 2016$1Quarterly
Oct 14, 2015Dec 7, 2015Nov 16, 2015$0.79Quarterly
Jul 28, 2015Sep 8, 2015Aug 17, 2015$0.79Quarterly
Mar 4, 2015Jun 5, 2015May 14, 2015$0.79Quarterly
Dec 17, 2014Mar 6, 2015Feb 12, 2015$0.79Quarterly
Oct 17, 2014Dec 5, 2014Nov 13, 2014$0.61Quarterly
Jul 25, 2014Sep 5, 2014Aug 14, 2014$0.61Quarterly
Mar 5, 2014Jun 6, 2014May 15, 2014$0.61Quarterly
Dec 13, 2013Mar 7, 2014Feb 13, 2014$0.61Quarterly
Jul 26, 2013Sep 6, 2013Aug 16, 2013$0.47Quarterly
Mar 6, 2013Jun 7, 2013May 16, 2013$0.47Quarterly
Dec 13, 2012Mar 7, 2013Feb 13, 2013$0.47Quarterly
Oct 10, 2012Dec 7, 2012Nov 15, 2012$0.36Quarterly

Related Companies

View additional S&P 500 companies similar to Amgen Inc (AMGN)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2024 Financhle. All Rights Reserved.